Emir Hadzijusufovic - Concepedia

Author

Emir Hadzijusufovic

Medical University of Vienna ORCID

Also Known As

E Hadzijusufovic, E. Hadzijusufovic, Emir Hadzijusufovic

111

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Medical University of Vienna University of Veterinary Medicine Vienna Ludwig Boltzmann Institute for Cardiovascular Research Heidelberg University University Hospital Heidelberg

About

Emir Hadzijusufovic is an author at Medical University of Vienna specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	19	748
2	Cell Biology	11	11	364
3	Health Sciences	2	2	41
4	Public Health	2	2	192
5	Allergy	2	2	82

Emir Hadzijusufovic

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors Peter Valent, Emir Hadzijusufovic, G. Schernthaner, Blood	2014	280
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis Georg Greiner, Bettina Sprinzl, Aleksandra Górska, Blood	2020	169
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site Emir Hadzijusufovic, Karin Albrecht-Schgoer, K. Huber, Leukemia Endothelial Cell PathobiologyInflammationVasculitisMedicineImmunology	2017	151
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study Wolfgang R. Sperr, Michael Kundi, Iván Álvarez‐Twöse, The Lancet Haematology Mast Cell DisorderClinical EpidemiologyDiagnosisPublic HealthRetrospective Cohort Study	2019	135
A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection Rosine Saleh, Ghaith Wedeh, Harald Herrmann, Blood	2014	100
The <i><scp>KIT</scp></i><scp>D</scp>816<scp>V</scp> allele burden predicts survival in patients with mastocytosis and correlates with the <scp>WHO</scp> type of the disease Gregor Hoermann, Karoline V. Gleixner, Graziella E. Dinu, Allergy	2014	97
Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536 Karoline V. Gleixner, Veronika Ferenc, Barbara Peter, Cancer Research Imatinib ResistanceHematological MalignancyChronic Myeloid LeukemiaBi 2536Medicine	2010	84
KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib Karoline V. Gleixner, Matthias Mayerhofer, Sabine Cerny‐Reiterer, Blood	2011	68
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth Barbara Peter, Georg E. Winter, K. Blatt, Leukemia Signal TransductionSignaling PathwayTarget Interaction ProfilingNeoplastic Mast CellsDistinct Effects	2015	59
Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells Karoline V. Gleixner, Laura Rebuzzi, Matthias Mayerhofer, Experimental Hematology Cancer ResearchSignaling PathwayMast Cell DisorderReceptor Tyrosine KinaseImmunology	2007	57

Page 1